KRDaewoong Pharmaceutical's botulinum toxin product Nabota has expanded into Kuwait, marking its seventh market in the Middle East and establishing the broadest commercial presence among Korean botulinum toxin producers in the region. The move follows successful entries into Saudi Arabia, the United Arab Emirates, Turkey, Qatar, Egypt, and Bahrain. Kuwait's market for botulinum toxin is valued at approximately 24 billion won ($16.6 million), with strong demand for premium aesthetic treatments driven by high income levels and purchasing power. Daewoong plans to leverage Kuwait as a strategic base for further expansion within the Gulf Cooperation Council (GCC) and strengthen Nabota's brand presence. The company will host a symposium in October to promote Nabota, targeting healthcare professionals and key opinion leaders.
Bias read (Center): The article presents factual information about Daewoong Pharmaceutical's business expansion into Kuwait without overtly favoring any political ideology. It focuses on economic and corporate development rather than political controversy, maintaining a balanced tone throughout.
